scAAVrh74 β-Sarcoglycan Delivery for Muscular Dystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for limb-girdle muscular dystrophy (LGMD2E) fail to effectively restore muscle function and reduce fibrosis, which leads to progressive muscle deterioration and loss of ambulation.
Innovation Solution
Administration of a recombinant adeno-associated virus (rAAV) vector, specifically scAAVrh74.MHCK7.hSGCB, to deliver the β-sarcoglycan gene systemically, promoting its expression and reducing fibrosis, thereby improving muscle function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for LGMD2E, then treatment simplicity is maintained, but muscle function restoration and fibrosis reduction are ineffective
Solution Approach 1:
The patent uses AAV vectors as intermediary carriers to deliver the β-sarcoglycan gene to muscle cells. The AAV vector system includes specific viral components (ITR sequences, promoter regions, capsid proteins) that mediate gene delivery and expression, transforming the treatment from direct protein replacement to indirect gene-mediated protein production, thereby improving treatment effectiveness while maintaining manageable complexity
Solution Approach 2:
The patent employs specific parameter optimizations including: (1) using self-complementary AAV (scAAV) architecture to enhance transgene expression efficiency, (2) selecting AAV rh.74 serotype for improved muscle tropism and transduction efficiency, (3) optimizing promoter strength and composition (CMV, MCK, MHCK7) to control gene expression levels, and (4) adjusting viral dose parameters (10^12 to 10^14 vg/kg) to achieve therapeutic effects while minimizing side effects
2Quantity of substance
If AAV vector dosage is increased to improve gene expression, then β-sarcoglycan expression increases, but risk of adverse effects increases
Solution Approach 1:
The patent establishes optimized dosage parameters ranging from 10^12 to 10^14 viral genomes per kilogram (vg/kg), with specific recommendations based on transduction efficiency targets. This parameter optimization allows achieving sufficient β-sarcoglycan expression levels (demonstrated as increased protein expression and improved muscle histology) while avoiding excessive dosing that could cause immune responses or off-target effects
Solution Approach 2:
The patent employs biomarker monitoring (serum creatine kinase levels, transgene expression levels) to assess treatment response and adjust dosing strategies. Clinical monitoring of muscle function improvement and expression levels provides feedback to optimize the balance between achieving therapeutic expression levels and minimizing adverse effects
3Area of stationary object
If systemic administration is used to achieve widespread gene delivery, then coverage of affected muscles is improved, but specificity of target tissue delivery decreases
Solution Approach 1:
The patent utilizes AAV capsid proteins (specifically AAV rh.74 serotype) as intermediary molecules that mediate between systemic circulation and muscle tissue target cells. The capsid structure contains specific receptor-binding domains that recognize muscle cell surface receptors, enabling the vector to navigate systemic circulation while maintaining affinity for muscle tissue, thus achieving both widespread coverage and target specificity
Solution Approach 2:
The patent achieves local quality enhancement by incorporating muscle-specific promoter elements (MCK, MHCK7) into the vector construct. These promoters ensure that even when the vector distributes systemically, transgene expression is preferentially activated in muscle cells rather than other tissue types, thereby maintaining delivery specificity despite systemic administration
4Reliability
If fibrosis is reduced through gene therapy, then muscle function improves, but time required for fibrosis reversal increases
Solution Approach 1:
The patent employs preliminary action by delivering the functional β-sarcoglycan gene before extensive irreversible fibrosis and muscle cell death occur. Early intervention with the AAV vector establishes continuous production of the dystrophin-associated protein complex, which prevents further sarcolemma fragility and secondary fibrosis, thereby reducing the overall time needed for functional improvement compared to late-stage treatment
Solution Approach 2:
The patent achieves continuous useful action through the persistent expression of β-sarcoglycan from the integrated AAV vector. The self-complementary AAV architecture and muscle-specific promoter ensure sustained transgene expression over months to years, providing continuous production of functional protein that progressively replaces fibrotic tissue and maintains muscle function, thereby accelerating overall recovery compared to intermittent treatments
Data Source
AI summary
Described herein are methods of treating muscular dystrophy comprising administering a recombinant AAV (rAAV) scAAVrh74.MHCK7.hSGCB vector, methods of expressing beta-sarcoglycan gene in a patient, pharmaceutical compositions comprising the rAAV, and methods of generating the rAAV. The disclosed methods reduce fibrosis and improve muscle function by restoring B-sarcoglycan expression in muscle tissues. The disclosure further provides preclinical studies in animal models, and a clinical trial involving systemic delivery of the vector to patients, which shows significant improvements in muscle pathology, force production, and overall activity in treated subjects.